HeartBeam, Inc., a medical technology company specializing in cardiac care, reported a net loss of $21.0 million for the fiscal year ending December 31, 2025, an increase of 8% from the previous year's loss of $19.4 million. The company's total operating expenses rose to $21.1 million, up 6% from $19.9 million in 2024. This increase was primarily driven by a 22% rise in research and development expenses, which reached $13.5 million, reflecting the company's ongoing investment in its innovative cardiac monitoring solutions. General and administrative expenses decreased by 13% to $7.7 million, attributed to lower consulting costs and a reduction in stock-based compensation.
HeartBeam's financial position showed improvement, with cash and cash equivalents increasing to approximately $4.4 million as of December 31, 2025, compared to $2.4 million at the end of 2024. The company raised $16.6 million through the sale of common stock during the year, contributing to its liquidity. However, the company expressed substantial doubt about its ability to continue as a going concern, citing that existing cash resources are insufficient to fund operations for the next twelve months without additional capital.
Strategically, HeartBeam is preparing for a limited market launch of its HeartBeam System, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. The company plans to focus on concierge and preventive cardiology groups for this initial rollout. Additionally, HeartBeam is pursuing an expansion of its product offerings, including a heart attack detection indication and an extended wear patch monitor, which are expected to enhance its market presence.
Operationally, HeartBeam's workforce increased from 16 to 17 employees with the recent hiring of Bryan Humbarger as Chief Commercial Officer. The company also announced its first commercial customer, ClearCardio, and initiated a pilot study for heart attack detection, enrolling patients to compare results from its device with standard ECGs. These developments are part of HeartBeam's broader strategy to establish itself in the growing market for ambulatory cardiac monitoring, which is projected to reach approximately $18 billion by 2030.
Looking ahead, HeartBeam aims to leverage its proprietary technology and data-rich repository to develop AI-based screening and prediction algorithms, enhancing its product offerings. The company remains focused on achieving critical clinical and regulatory milestones while managing its cash resources effectively to support its growth strategy.
About HeartBeam, Inc.
HeartBeam, Inc. develops portable, FDA-cleared cardiac monitoring devices utilizing proprietary technology to capture high-fidelity ECG signals from three directions. Its products enable remote detection and diagnosis of cardiac conditions, including arrhythmias and heart attacks, through user-friendly, cable-free hardware and cloud-based software. Targeting healthcare providers and patients, the company aims to improve early diagnosis, reduce healthcare costs, and expand advanced cardiac diagnostics outside clinical settings.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.